Retrospective Evaluation of Cycled Resin in Viral Clearance Studies—A Multiple Company Collaboration—Post ICH Q5A(R2) Review

References

1. 1.↵
   1. Anderson K. P.,
   2. Low M.-A. L.,
   3. Lie Y. S.,
   4. Keller G.-A.,
   5. Dinowitz M.

   Endogenous Origin of Defective Retrovirus-Like Particles from a Recombinant Chinese Hamster Ovary Cell Line. Virology 1991, 181 (1), 305–311.

   OpenUrlPubMed
2. 2.↵
   1. Garnick R. L.

   Raw Materials as a Source of Contamination in Large Scale Cell Culture. Dev. Biol. Stand. 1998, 93, 21–29.

   OpenUrlPubMedWeb of Science
3. 3.↵
   1. Nims R. W.

   Detection of Adventitious Viruses in Biologicals – A Rare Occurrence. Dev. Biol. 2006, 123, 153–164.

   OpenUrl
4. 4.↵
   European Medicines Agency, Guideline on Virus Safety Evaluation of Biotechnology Investigational Medicinal Products. EMA: London, 2008.
5. 5.↵
   European Medicines Agency, Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses; CPMP/BWP/268/95; EMA: London, 1996.
6. 6.↵
   U.S. Food and Drug Administration, Points to Consider in the Manufacture and Testing of Monoclonal Antibodies for Human Use, Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 1997.
7. 7.↵
   International Conference for Harmonisation, Quality Guideline Q5A: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH: Geneva, 1998.
8. 8.↵
   1. Blümel J.,
   2. Brorson K.

   Session 2: Company-Specific Data on Cycled Resin Testing. PDA J. Pharm. Sci. Technol. 2016, 70 (5), 428–442.

   OpenUrlFREE Full Text
9. 9.↵
   1. Brorson K.,
   2. Brown J.,
   3. Hamilton E.,
   4. Stein K. E.

   Identification of Protein A Media Performance Attributes That Can Be Monitored as Surrogates for Retrovirus Clearance during Extended Re-Use. J. Chromatogr. A 2003, 989 (1), 155–163.

   OpenUrlPubMed
10. 10.↵
    European Medicines Agency, Meeting Report: Joint BWP/QWP Workshop with Stakeholders in Relation to Prior Knowledge and Its Use in Regulatory Applications; EMA/CHMP/BWP/187162/2018; EMA: London, 2018.
11. 11.↵
    1. Lute S.,
    2. Norling L.,
    3. Hanson M.,
    4. Emery R.,
    5. Stinson D.,
    6. Padua K.,
    7. Blank G.,
    8. Chen Q.,
    9. Brorson K.

    Robustness of Virus Removal by Protein A Chromatography Is Independent of Media Life Time. J. Chromatogr. A 2008, 1205 (1–2), 17–25.

    OpenUrlPubMed
12. 12.↵
    1. Kelley B. D.,
    2. Jakubik J.,
    3. Vicik S.

    Viral Clearance Studies on New and Used Chromatography Resins: Critical Review of a Large Dataset. Biologicals 2008, 36 (2), 88–98.

    OpenUrlPubMed
13. 13.↵
    1. Norling L.,
    2. Lute S.,
    3. Emery R.,
    4. Khuu W.,
    5. Voisard M.,
    6. Xu Y.,
    7. Chen Q.,
    8. Blank G.,
    9. Brorson K.

    Impact of Multiple Re-Use of Anion-Exchange Chromatography Media on Virus Removal. J. Chromatogr. A 2005, 1069 (1), 79–89.

    OpenUrlPubMed
14. 14.↵
    1. Roush D.

    Viral Clearance Using Traditional, Well-Understood Unit Operations: Session 1.2. Anion Exchange Chromatography; and Session 1.3. Protein A Chromatography. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 154–162.

    OpenUrlFREE Full Text
15. 15.↵
    1. Miesegaes G.,
    2. Lute S.,
    3. Brorson K.

    Analysis of Viral Clearance Unit Operations for Monoclonal Antibodies. Biotechnol. Bioeng. 2010, 106 (2), 238–246.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Zhang M.,
    2. Lute S.,
    3. Norling L.,
    4. Hong C.,
    5. Safta A.,
    6. O'Connor D.,
    7. Bernstein L. J.,
    8. Wang H.,
    9. Blank G.,
    10. Brorson K.,
    11. Chen Q.

    A Novel, Q-PCR Based Approach to Measuring Endogenous Retroviral Clearance by Capture Protein A Chromatography. Biotechnol. Bioeng. 2009, 102 (5), 1438–1447.

    OpenUrlPubMed
17. 17.↵
    1. Zhang M.,
    2. Miesegaes G. R.,
    3. Lee M.,
    4. Coleman D.,
    5. Yang B.,
    6. Trexler-Schmidt M.,
    7. Norling L.,
    8. Lester P.,
    9. Brorson K. A.,
    10. Chen Q.

    Quality by Design Approach for Viral Clearance by Protein A Chromatography. Biotechnol. Bioeng. 2014, 111 (1), 95–103.

    OpenUrl
18. 18.↵
    1. Bach J.,
    2. Connell-Crowley L.

    Clearance of the Rodent Retrovirus, XMuLV, by Protein A Chromatography. Biotechnol. Bioeng. 2015, 112 (4), 743–750.

    OpenUrl
19. 19.↵
    1. Strauss D. M.,
    2. Lute S.,
    3. Tebaykina Z.,
    4. Frey D. D.,
    5. Ho C.,
    6. Blank G. S.,
    7. Brorson K.,
    8. Chen Q.,
    9. Yang B.

    Understanding the Mechanism of Virus Removal by Q Sepharose Fast Flow Chromatography during the Purification of CHO-Cell Derived Biotherapeutics. Biotechnol. Bioeng. 2009, 104 (2), 371–380.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Strauss D. M.,
    2. Gorrell J.,
    3. Plancarte M.,
    4. Blank G. S.,
    5. Chen Q.,
    6. Yang B.

    Anion Exchange Chromatography Provides a Robust, Predictable Process to Ensure Viral Safety of Biotechnology Products. Biotechnol. Bioeng. 2009, 102 (1), 168–175.

    OpenUrlCrossRefPubMed
21. 21.↵
    U.S. Pharmacopeial Convention, General Chapter <1050.1> Viral Clearance Procedures. In USP 39–NF 34, USP: Rockville, MD, 2016; pp 7745–7755.
22. 22.↵
    Parenteral Drug Association Inc. Technical Report No. 47: Preparation of Virus Spikes Used for Viral Clearance Studies; Bethesda, MD, 2010.
23. 23.
    1. Nicola A. V.,
    2. Peng C.,
    3. Lou H.,
    4. Cohen G. H.,
    5. Eisenberg R. J.

    Antigenic Structure of Soluble Herpes Simplex Virus (HSV) Glycoprotein D Correlates with Inhibition of HSV Infection. J. Virol. 1997, 71 (4), 2940–2946.

    OpenUrlAbstract/FREE Full Text
24. 24.
    1. Taylor D. H.,
    2. Bosmann H. B.

    Measurement of the Electrokinetic Properties of Vaccinia and Reovirus by Laser-Illuminated Whole-Particle Microelectrophoresis. J. Virol. Methods 1981, 2 (5), 251–260.

    OpenUrlPubMed
25. 25.
    1. Venkatakrishnan B.,
    2. Yarbrough J.,
    3. Domsic J.,
    4. Bennett A.,
    5. Bothner B.,
    6. Kozyreva O. G.,
    7. Samulski R. J.,
    8. Muzyczka N.,
    9. McKenna R.,
    10. Agbandje-McKenna M.

    Structure and Dynamics of Adeno-Associated Virus Serotype 1 VP1-Unique N-Terminal Domain and Its Role in Capsid Trafficking. J. Virol. 2013, 87 (9), 4974–4984.

    OpenUrlAbstract/FREE Full Text
26. 26.
    1. Seabrook E. J.,
    2. Turton T. N.,
    3. Conlan B.

    Factor VIII Separation. U.S. Patent 7,144,487, December 5, 2006.
27. 27.
    1. Michen B.,
    2. Graule T.

    Isoelectric Points of Viruses. J. Appl. Microbiol. 2010, 109 (2), 388–397.

    OpenUrlCrossRefPubMed
28. 28.
    1. Walsh A. A.

    Charge Differences Between AMuLV and XMuLV Measured Through Viral Clearance Using Anion Exchange Chromatography. Master Thesis, Villanova University, 2016.
29. 29.↵
    International Conference for Harmonisation. ICH Q5A(R2) Guideline on Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin – Step 5. ICH: Geneva, 2024.
30. 30.↵
    1. Ajayi O. O.,
    2. Johnson S. A.,
    3. Faison T.,
    4. Azer N.,
    5. Cullinan J.,
    6. Dement-Brown J.,
    7. Lute S. C.

    An Updated Analysis of Viral Clearance Unit Operations for Biotechnology Manufacturing. Curr. Res. Biotechnol. 2022, 4, 190–202. (4),

    OpenUrl